

Volution Group

Investing for growth

Investment – organic and inorganic – is a key theme of Volution's H117 results, contributing to healthy y-o-y growth. Volution has the financial capacity to continue this strategy and, in more mixed market conditions, acquisitions may be more significant drivers for premium earnings growth.

Underlying growth boosted by acquisitions and FX

H117 headline growth rates were strongly ahead in all reported Ventilation Group categories and acquisitions largely boosted UK progress. L-f-Is (ex-favourable acquisition and FX effects) were more of a mixed bag; we estimate that European revenue was + c 5.2% (with both subregions ahead) and the UK was +1.4% (with positive exports and residential new build sectors, partly offset by weakness in residential RMI, with commercial flat). Underlying profitability is more difficult to read; there was some gross margin improvement (at least partly due to US\$ transactional hedging last year), but there has also been P&L investment in sales resource. Acquisitions (Welair, Diffusion, NVA – all prior year, and Breathing Buildings – December 2016) chipped in c £12m of c £78m revenue for the Ventilation Group and all are understood to be trading ahead of pre-acquisition levels, which should feed into I-f-Is in due course. Torin-Sifan is in a product transition phase. Volution ended H117 with c £40m net debt (1.1x trailing EBITDA), with free cash flow funding acquisition spend of £11.6m in the period.

Clear acquisition and group integration strategy

Management has expounded a clear acquisition strategy, and has successfully identified and landed some of its targets to date. As well as integrating individual acquisitions, we like the fact that broader steps are being taken, including implementing a new ERP system (almost complete) and consolidating some UK manufacturing operations. The latter move is expected to cost c £1.75m (with a mid-2018 completion date), entails minimal capex and, with no net operating cost impact, will increase floor space of the operations to be combined by c 25%. Together, these actions provide an enhanced platform for further growth.

Valuation: Anticipating growth

Since June last year, Volution's share price has performed broadly in line with, but slightly ahead of the FTSE All-Share index and is up c 9% ytd. In our view, the rating is probably anticipating further use of the company's financial capacity to make earnings-enhancing acquisitions. Ahead of this, Volution is trading on a low-teens P/E multiple (and a PEG in excess of 2x), with a comparatively low yield for the subsector, but with scope to grow it reasonably quickly in most scenarios.

Consensus estimates						
Year end	Revenue (£m)	PBT* (£m)	EPS* (p)	DPS (p)	P/E (x)	Yield (%)
07/15	130.2	22.0	11.0	3.3	16.2	1.9
07/16	154.5	25.1	12.6	3.8	14.1	2.1
07/17e	179.3	33.7	13.3	4.0	13.4	2.2
07/18e	186.0	35.6	14.1	4.2	12.6	2.4

Source: Bloomberg. Note: Company-defined adjusted basis.

Construction & materials

24 March 2017

Price 178.13p Market cap £356m



Share details Code FAN Listing LSE Shares in issue 200.0m

Business description

Volution Group is a leading supplier of branded ventilation products to the residential and commercial construction markets. Geographically, the UK represented c 55% of H117 revenue, the Nordics c 17% and Central Europe c 15%, while its OEM division (Torin-Sifan c 12%) supplies mechanical products (motors, fans, blowers) to other group companies and external heating and ventilation OEMs.

Bull

- Leading positions in the supply of ventilation products into residential construction markets in the UK, Sweden and Germany.
- European operations performing well and good UK residential new build and export exposure.
- Financial capacity for further complementary acquisitions.

Bear

- UK residential RMI spending appears weak.
- Commercial sector currently flat, but appears to be improving.
- Torin-Sifan has been constrained by migration to new product offering, but deliveries now underway.

Analysts

Toby Thorrington +44 (0)20 3077 5721 Roger Johnston +44 (0)20 3077 5722

industrials@edisongroup.com

EDISON QUICKVIEWS ARE NORMALLY ONE-OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.



Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited (Edison Commission).

DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australial by Edison Australian Corporations Act. The Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australial by Edison Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Securities and Exchange Commission. Edison Ous Testes upon the "publishers' exclusion" from the definition of investment adviser under Securities and Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advise